BACKGROUND: Routine rotavirus vaccination of US infants began in 2006. We conducted active, population-based surveillance for rotavirus gastroenteritis hospitalizations in 3 US counties to assess vaccine impact. METHODS: Children <36 months old hospitalized with diarrhea and/or vomiting were enrolled from January through June each year during the period 2006-2009 and tested for rotavirus. Age-stratified rates of hospitalization for rotavirus infection were compared with corresponding vaccination coverage among a control group of children with acute respiratory illness. To assess direct and indirect benefits, vaccination coverage rates in the control group were multiplied by vaccine effectiveness estimates to calculate expected reductions in the rate of hospitalization for rotavirus infection. Rotavirus serotypes were compared across years. RESULTS: Compared with 2006, a significant reduction in rates of hospitalization for rotavirus infection (P < .001) was observed in 2008 among all age groups. There was an 87% reduction in the 6-11-month-old age group (coverage, 77%), a 96% reduction in the 12-23-months-old age group (coverage, 46%), and a 92% reduction in the 24-35-month-old age group (coverage, 1%), which exceeded reductions expected on the basis of coverage and vaccine effectiveness estimates. Age-specific rate reductions were nearly equivalent to those expected on the basis of age-specific vaccine coverage in 2009. Predominant strains varied annually: G1P[8] (91%) in 2006; G1P[8] (45%) and G12P[8] (36%) in 2007; G1P[8] (89%) in 2008; and G3P[8] (43%), G2P[4] (34%), and G9P[8] (27%) in 2009. CONCLUSIONS: Rotavirus vaccination has dramatically decreased rates of hospitalization for rotavirus infection among children in these US counties. In 2008, reductions were prominent among both vaccine-eligible age groups and older, largely unvaccinated children; the latter likely resulted from indirect protection. Although rates among age groups eligible for vaccination remained low in 2009, indirect benefits disappeared.
BACKGROUND: Routine rotavirus vaccination of US infants began in 2006. We conducted active, population-based surveillance for rotavirus gastroenteritis hospitalizations in 3 US counties to assess vaccine impact. METHODS:Children <36 months old hospitalized with diarrhea and/or vomiting were enrolled from January through June each year during the period 2006-2009 and tested for rotavirus. Age-stratified rates of hospitalization for rotavirus infection were compared with corresponding vaccination coverage among a control group of children with acute respiratory illness. To assess direct and indirect benefits, vaccination coverage rates in the control group were multiplied by vaccine effectiveness estimates to calculate expected reductions in the rate of hospitalization for rotavirus infection. Rotavirus serotypes were compared across years. RESULTS: Compared with 2006, a significant reduction in rates of hospitalization for rotavirus infection (P < .001) was observed in 2008 among all age groups. There was an 87% reduction in the 6-11-month-old age group (coverage, 77%), a 96% reduction in the 12-23-months-old age group (coverage, 46%), and a 92% reduction in the 24-35-month-old age group (coverage, 1%), which exceeded reductions expected on the basis of coverage and vaccine effectiveness estimates. Age-specific rate reductions were nearly equivalent to those expected on the basis of age-specific vaccine coverage in 2009. Predominant strains varied annually: G1P[8] (91%) in 2006; G1P[8] (45%) and G12P[8] (36%) in 2007; G1P[8] (89%) in 2008; and G3P[8] (43%), G2P[4] (34%), and G9P[8] (27%) in 2009. CONCLUSIONS: Rotavirus vaccination has dramatically decreased rates of hospitalization for rotavirus infection among children in these US counties. In 2008, reductions were prominent among both vaccine-eligible age groups and older, largely unvaccinated children; the latter likely resulted from indirect protection. Although rates among age groups eligible for vaccination remained low in 2009, indirect benefits disappeared.
Authors: Catherine Yen; Jacqueline E Tate; Terri B Hyde; Margaret M Cortese; Benjamin A Lopman; Baoming Jiang; Roger I Glass; Umesh D Parashar Journal: Hum Vaccin Immunother Date: 2014-04-22 Impact factor: 3.452
Authors: Stephanie Donauer; Daniel C Payne; Kathryn M Edwards; Peter G Szilagyi; Richard W Hornung; Geoffrey A Weinberg; James Chappell; Caroline B Hall; Umesh D Parashar; Mary Allen Staat Journal: Vaccine Date: 2013-04-12 Impact factor: 3.641
Authors: Michelle W Parker; Joshua K Schaffzin; Andrea Lo Vecchio; Connie Yau; Karen Vonderhaar; Amy Guiot; William B Brinkman; Christine M White; Jeffrey M Simmons; Wendy E Gerhardt; Uma R Kotagal; Patrick H Conway Journal: Pediatrics Date: 2013-03 Impact factor: 7.124
Authors: Ui Yoon Choi; Soo Young Lee; Sang Hyuk Ma; Young Taek Jang; Jae Young Kim; Hwang Min Kim; Jong Hyun Kim; Dong Soo Kim; Yong Soo Kim; Jin Han Kang Journal: Eur J Pediatr Date: 2013-02-27 Impact factor: 3.183
Authors: Daniel C Payne; Julie A Boom; Mary Allen Staat; Kathryn M Edwards; Peter G Szilagyi; Eileen J Klein; Rangaraj Selvarangan; Parvin H Azimi; Christopher Harrison; Mary Moffatt; Samantha H Johnston; Leila C Sahni; Carol J Baker; Marcia A Rench; Stephanie Donauer; Monica McNeal; James Chappell; Geoffrey A Weinberg; Azadeh Tasslimi; Jacqueline E Tate; Mary Wikswo; Aaron T Curns; Iddrisu Sulemana; Slavica Mijatovic-Rustempasic; Mathew D Esona; Michael D Bowen; Jon R Gentsch; Umesh D Parashar Journal: Clin Infect Dis Date: 2013-03-13 Impact factor: 9.079
Authors: Joseph A Lewnard; Benjamin A Lopman; Umesh D Parashar; Naor Bar-Zeev; Prasanna Samuel; M Lourdes Guerrero; Guillermo M Ruiz-Palacios; Gagandeep Kang; Virginia E Pitzer Journal: J Infect Dis Date: 2017-08-01 Impact factor: 5.226